Less is more in the case of this cancer treatment. The most common form of cancer among men in the US, after skin cancer, ...

CHICAGO -- Patients with advanced prostate cancer treated with enzalutamide (Xtandi) had a significantly greater decline in ...

The Alliance for Clinical Trials in Oncology has launched the ASPIRE trial-a large-scale, Phase III clinical study investigating whether adding chemotherapy to current standard treatments can extend ...

Over half of patients in a randomized trial switch from enzalutamide to darolutamide because of cognitive issues; no one switches in the opposite direction.

Researchers with the James P. Allison Institute at The University of Texas MD Anderson Cancer Center have discovered a new ...

A landmark £42 million trial aimed at revolutionising prostate cancer screening has officially begun in the UK, with the first eligible men now invited to participate. Health Secretary Wes Streeting ...

Recently, the research group led by Dr. Dechao Feng, Lecturer at University College London (UCL) and Distinguished Research ...

Approximately one in eight American men will be diagnosed with prostate cancer during their lifetime. For most of them, if ...

A recent post hoc analysis assesses whether PSA changes can predict survival outcomes in patients with metastatic or very high risk nonmetastatic prostate cancer.

A new blood test could help doctors identify whether a treatment for advanced prostate cancer is failing weeks earlier than ...

A new experimental drug is showing potential in treating prostate cancer and possibly other forms of the disease. A new immunotherapy drug used in a prostate cancer clinical trial is showing early ...

A new podcast fronted by writer, comedian and broadcaster Jon Holmes is aiming to help men better understand their prostate cancer treatment options ...